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PACAP and migraine headache:
immunomodulation of neural circuits in
autonomic ganglia and brain parenchyma
James A. Waschek1*, Serapio M. Baca2* and Simon Akerman3,4*
Abstract
The discovery that intravenous (IV) infusions of the neuropeptide PACAP-38 (pituitary adenylyl cyclase activating
peptide-38) induced delayed migraine-like headaches in a large majority of migraine patients has resulted in considerable
excitement in headache research. In addition to suggesting potential therapeutic targets for migraine, the finding provides
an opportunity to better understand the pathological events from early events (aura) to the headache itself. Although
PACAP-38 and the closely related peptide VIP (vasoactive intestinal peptide) are well-known as vasoactive molecules,
the dilation of cranial blood vessels per se is no longer felt to underlie migraine headaches. Thus, more recent research
has focused on other possible PACAP-mediated mechanisms, and has raised some important questions. For example,
(1) are endogenous sources of PACAP (or VIP) involved in the triggering and/or propagation of migraine headaches?;
(2) which receptor subtypes are involved in migraine pathophysiology?; (3) can we identify specific anatomical circuit(s)
where PACAP signaling is involved in the features of migraine? The purpose of this review is to discuss the possibility, and
supportive evidence, that PACAP acts to induce migraine-like symptoms not only by directly modulating nociceptive neural
circuits, but also by indirectly regulating the production of inflammatory mediators. We focus here primarily on postulated
extra-dural sites because potential mechanisms of PACAP action in the dura are discussed in detail elsewhere (see X, this
edition).
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Review
Introduction
Primary headaches, such as migraine and the trigeminal
autonomic cephalalgias (TACs), are highly prevalent and
debilitating neurological disorders that cause significant
quality of life burdens for the sufferers [49, 101]. While
their pathophysiology is not fully understood, the
headache component is generally considered to involve
neurovascular mechanisms. Migraine pathophysiology,
however, most likely starts within the brain, as suggested
by premonitory symptoms [47], complementary imaging
studies [92], and by the nature of typical triggers, such
as stress, sleep deprivation, skipping meals, and even
over-sleeping [70]. Two mechanistic steps regarding the
pathophysiology of the headache in both migraine and
TACs are generally now accepted. First, headache pain is
mediated by activation and sensitization of the trigemi-
novascular pain pathway [57, 108, 109], i.e., the sensory
nerves that innervate the cranial vasculature, particularly
the intracranial dural vasculature and large cerebral
arteries, as well as extracranial blood vessels such as the
temporal artery. Second, the experience of headache
likely involves the release of sensory neuropeptides,
including calcitonin gene-related peptide (CGRP),
vasoactive intestinal peptide (VIP) and also pituitary ad-
enylate cyclase-activating peptide (PACAP) [52–56, 154].
However, the mechanisms of brain dysfunction that lead
to these primary headache disorders, and more specific-
ally to activation of the trigeminovascular pain pathway,
remain largely unknown.
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Inflammation and primary headaches
The idea that inflammatory processes are involved in
headache was discussed in the literature at least as early as
the 1950s, and was summarized with respect to migraine
by Moskowitz in 1984 [100]. The term “neurogenic
inflammation” (NI) has been applied in migraine research
and was originally defined as a physiological mechanism
resulting in dilation, plasma protein extravasation (PPE)-
evoked oedema, mast cell degranulation, as well as other
manifestations mediated by the release of neuropeptides
from peripheral and central afferent nerve terminals.
Support for this mechanism in migraine is predominantly
based on animal studies, and historically revolves around
mainly dural-mediated mechanisms. This posits that a
sterile inflammatory state is induced by neuronal activity
in or around the dural meninges, and underlies the
sustained activation of peripheral meningeal nociceptors.
This ultimately leads to sensitization of trigeminal primary
afferents, as well as second-order central trigeminovascu-
lar neurons [24, 113]. This idea is clearly supported by
animal experiments in which application of a mixture of
inflammatory mediators to the dura mater leads to periph-
eral and central trigeminovascular sensitization [25, 131].
An important role for neuro-inflammation is also indir-
ectly supported by findings of increased levels of several
pro-inflammatory mediators in the cephalic venous
outflow during spontaneous migraine [120], and by the
efficacy of non-steroidal anti-inflammatory drugs in acute
migraine treatment [51, 58, 112], as well as their success
in reversing peripheral and central sensitization in animal
models [77, 78].
The presence of pro-inflammatory mechanisms and
release of mediators within and around the dural micro-
environment, and its subsequent effects on trigeminovascu-
lar neurons, are very likely to cause cephalic pain similar to
migraine headache. That said, when the individual compo-
nent parts of NI are assessed as potential contributors to
eventual trigeminovascular activation and primary head-
aches, their contributions appear less clear. For example,
the vasodilation of dural blood vessels was long thought to
be responsible for throbbing head pain, particularly in
migraine. However, more recent studies demonstrate that
meningeal vessels do not necessarily dilate during spontan-
eous [10] or experimentally-triggered migraine attacks
[123]; intracranial vessels show only a slight dilation that is
unaffected by sumatriptan treatment [10]. Also, the throb-
bing and pulsatile nature of migraine headache is not
coupled to the frequency of arterial pulsations [97, 98], but
rather appear coupled to endogenous brain oscillations
related to alpha power [98]. Finally, although several vaso-
active drugs cause cranial arterial vasodilation and subse-
quently trigger migraine, including nitroglycerin [76],
CGRP [14, 85], and PACAP [11, 124], VIP [11, 114] does
not trigger a delayed migraine headache in patients. Indeed,
in a recent preclinical study it was found that both VIP and
PACAP similarly cause short-lived (1–5 min) vasodilation
of meningeal arteries, yet only PACAP was able to trigger a
delayed, by 90 min, activation and sensitization of central
trigeminovascular neurons [5].
Inhibition of dural PPE was once a major platform
used in screening the efficacy of drugs such as sumatrip-
tan for the treatment of migraine [26, 27, 94]. Dural PPE
can be mediated by trigeminal ganglion stimulation, or
the systemic application of various chemical mediators,
including substance P, capsaicin and neurokinin A [93].
However, drugs known to trigger migraine, including
CGRP and prostaglandin E2 (PGE2) [12] do not cause
dural PPE, and there is no evidence of release of
substance P in cephalic venous outflow during spontan-
eous migraine [56], in contrast to CGRP and PGE2.
Furthermore, several drug classes screened as potential
acute migraine therapeutics, defined by their ability to
inhibit dural PPE, including specific extravasation inhibi-
tors (i.e., conformationally restricted analogues of
triptans) [42, 118], neurokinin 1 receptor antagonists
[60, 61], and inducible nitric oxide synthase inhibitors
[72], were all ineffective clinically as either acute or
preventive treatments.
Despite these negative outcomes arising from using
PPE as a surrogate for inflammation in migraine, dural
mast cell degranulation clearly represents a relevant
mechanism that might lead to activation and sensitization
of the trigeminovascular pain pathway. Upon activation,
mast cells are known to degranulate and release a host of
inflammatory mediators. Exogenous migraine triggers,
CGRP, NTG and PACAP, can cause dural mast cell
degranulation [18, 110, 116], and subsequent release of
inflammatory mediators. Furthermore, specific dural
mast cell degranulation produces a long-lasting
sensitization of trigeminal primary afferent neurons
[88, 156], suggesting this neuro-inflammatory mechan-
ism may be directly involved in mediating the under-
lying neurophysiological changes that results in primary
headache, particularly in migraine.
The important role of neuropeptides, such as CGRP
and PACAP, in the pathophysiology of migraine seems
undeniable, and it is clear that this may involve elements
of neurogenic dural inflammation. However, beyond the
dura mater and the trigeminovascular pain pathway
(topics of other reviews within this special issue, and
also reviewed recently [133]), PACAP-regulated neuro-
inflammatory mechanisms within deeper brain struc-
tures may be involved in mediating these dural changes,
such as in the brainstem, cortex, or autonomic projec-
tions, which lead to trigeminovascular activation.
Furthermore, other neuro-inflammatory mechanisms
within these structures may directly mediate activation
of the trigeminovascular pain pathway without
Waschek et al. The Journal of Headache and Pain  (2018) 19:23 Page 2 of 13
impacting the dural vasculature. The aim of the re-
mainder of this review is to focus on the specific role of
PACAP in neurogenic inflammation. Furthermore, we
will focus on how PACAP-mediated neurogenic inflam-
mation in deeper brain structures may contribute to
the underlying nociceptive neurophysiology of primary
headaches, especially in migraine.
PACAP signaling
PACAP-38 is a 38 amino acid long neuropeptide originally
isolated in 1989 in a search for novel factors produced in
the hypothalamus that could stimulate cAMP production
in pituitary cells. Upon sequencing, PACAP (gene name
Adcyap1) was found to be 68% homologous to the neuro-
peptide vasoactive intestinal peptide (gene name VIP). A
27 amino acid long C-terminal truncated form, PACAP-
27, is internally cleaved from PACAP-38, and is generally
produced in lower but significant concentrations in many
of the same sites as PACAP-38, and has similar biological
activities and receptor binding affinities. The two PACAP
species are exceptionally-well conserved across evolution.
For example, human PACAP-27 is 97% identical to that of
amphibians [75] and 90% to that of hydra and other
cnidarians [28]. PACAP (both forms) bind to three differ-
ent receptors: PAC1, which specifically interacts with
PACAP, and VPAC1 and VPAC2, which bind PACAP and
VIP with approximately equal affinity [67]. After its
discovery, PACAP was found to function in vertebrates as
a neurotransmitter/neuromodulator in many processes in
the central and peripheral nervous systems, such as in the
control of circadian rhythms, learning and memory, and
reproduction, and has been implicated in multiple forms
of stress, including metabolic, hemodynamic, and emo-
tional stress (reviewed in [32, 35, 44, 65, 68, 102, 115, 125,
132, 138, 145, 149]). In addition, considerable evidence in-
dicates that PACAP functions broadly in brain develop-
ment to regulate cell proliferation, maturation and
survival [9, 44, 106, 129, 146–148], and to provide neuro-
protection and promote repair after injury (reviewed in
[32, 115, 125]). As discussed below, considerable evidence
indicates that another important function of VIP and
PACAP is to modulate the activity of inflammatory cells.
The development and clinical testing of PACAP and/or
VIP antagonists for migraine will need to carefully take into
account how a widespread and/or uncontrolled blockade of
these receptors might affect the known homeostatic activ-
ities of these endogenously-expressed peptides.
Which receptor subtype/s mediate the migraine-inducing
action of PACAP?
As discussed, the perception of migraine headache is
believed to critically involve enhanced sensitivity of trigemi-
nal pain circuits. PACAP receptors are expressed in trigem-
inal, sympathetic, and parasympathetic nerve terminals in
the dura, but also in neurons at several levels of the
migraine circuity within the CNS (Figs. 1 and 2). Potential
access to intravenously-administered PACAP to the CNS is
discussed below. In addition to their presence on neurons,
receptors for PACAP (most prominently, VPAC1, and
VPAC2, but also PAC1) are expressed on nearly all cells of
the immune system, including the resident macrophages of
the brain, microglia. Moreover, all three receptors are
expressed on astrocytes, which under some conditions are
known to produce inflammatory mediators.
Pharmacological studies suggest PACAP receptor sub-
types might mediate the action of systemically administered
PACAP. Intravenous infusions of PACAP-38, but not VIP,
reliably and repeatedly induce delayed migraine-like head-
aches. Given that the PAC1 receptors are at least two
orders of magnitude more selective for PACAP than
VPAC1 and VPAC2 receptors, it is tempting to conclude
that PACAP acts in this situation via action on PAC1 recep-
tors. However, such a conclusion is premature. A trivial,
but as yet untested mechanism is that PACAP may be more
stable in the blood than VIP. This is supported by pharma-
cokinetic findings which indicate a half-life of two minutes
for VIP [69] and 5–10 min for PACAP [89]. Thus, infusion
of PACAP might be expected to produce considerably
higher steady state blood concentrations than equimolar
infusions of VIP. Another possibility is that PACAP has
better access to the relevant sites of action, for example by
way of better penetration of the blood-brain-barrier. More-
over, putative PACAP and VIP receptors on mast cells and
neutrophils do not at all correspond to known receptors for
these peptides, showing activation in response to both
receptor agonists and antagonists [18]. Finally, recent
research shows that PACAP can penetrate cells raising the
possibility that PACAP might act on an as yet unknown
intracellular receptor [40]. Thus, further investigation is
needed to identify the receptor or receptors that mediate
the ability of intravenous administration of PACAP to trig-
ger migraine-like headaches.
Immunomodulatory actions of PACAP and VIP in the
periphery
The preponderance of literature describing the importance
of PACAP and VIP on inflammation has addressed their
roles in regulating innate and adaptive immune processes
in the periphery (extensively reviewed in ref. [35]). In this
regard, PACAP and/or VIP are expressed in autonomic
neurons that innervate all major lymphoid structures,
including lymph nodes, spleen, thymus, and bone marrow,
and nearly all immune cell types express one or more VIP
and PACAP receptor subtypes. Under some circumstances
the peptides themselves appear to be expressed in the mast
cells and lymphocytes, where they may function like cyto-
kines or chemokines. One of the earliest-studied activities
of these peptides on immune function was their capacity to
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inhibit inflammation through their action on macrophages.
These cells constitutively express VPAC1 and PAC1 recep-
tors, and when exposed to an inflammatory stimulus,
express VPAC2. Early studies reported that VIP and
PACAP inhibited the production of TNF-α and IL-6 in
macrophage cultures in response to lipopolysaccharide
(LPS). Later, these peptides were shown to increase the
synthesis and release of anti-inflammatory molecules like
IL-10 and the IL-1 receptor antagonist (IL-1Ra), leading to
a decrease in the inflammatory response [34]. VIP and
PACAP were also shown to inhibit the production of
several chemokines in macrophage cultures stimulated with
LPS [33]. The ability of PACAP to trigger mast cell de-
granulation is reviewed elsewhere in this series (Jansen-Ole-
sen). A few studies have addressed the potential actions of
these peptides on other innate immune cells including,
Fig. 1 Anatomy and PACAP-mediated cranial trigeminal-autonomic mechanisms mediating dural-trigeminovascular activation. Cranial autonomic
symptoms are thought to be mediated, in part, by activation of the trigeminal-autonomic reflex; a reflex connection from the trigeminal nucleus
caudalis (TNC; grey neuron), via the superior salivatory nucleus (SuS; green diamond), which provides an autonomic parasympathetic projection
to the cranial vasculature. This is predominantly through the greater petrosal nerve (green neuron) and its relay with the sphenopalatine ganglion
(SPG), but also via the facial (VIIth cranial) nerve (sky blue neuron). Descending projections from hypothalamic nuclei (red and yellow neurons) in-
cluding the posterior (PH), paraventricular (PVN), lateral (LH), dorsomedial (DMH) and pre-optic hypothalamic nuclei (PON), to the TCC (red projec-
tions) and SuS (yellow projections) neurons, are thought to modulate and control both trigeminovascular nociceptive transmission (purple
network of neurons) and parasympathetic (green) autonomic projections to the cranial vasculature that result indirectly or directly, respectively, in
cranial autonomic symptoms ipsilateral to head pain. Cranial autonomic symptoms, and activation of the cranial autonomic projection, are
thought to modulate or even trigger activation of dural neuro-inflammatory mechanisms, which mediate dural trigeminovascular activation result-
ing in headache in primary headache. Activation of preganglionic SuS neurons stimulates the release of various neurotransmitter (light blue dots),
including PACAP-38, VIP, neuropeptide (NPY), acetylcholine (ACh), and nitric oxide (NO) from nerve terminals of postganglionic parasympathetic
neurons in the SPG. Their release is thought to mediate meningeal vasodilation and dural mast cell degranulation (brown dots), the production
of COX-1 from mast cells and COX-2 from macrophage, causing the local release of inflammatory mediators, together capable of activating pial
and dural branches of the trigeminal nerve. The presence of mRNA and/or protein for VPAC1/2 and PAC1 receptors in human/rat middle menin-
geal arteries, trigeminal ganglia and trigeminal nucleus caudalis (TNC), and sphenopalatine ganglia (SPG), mast cells and macrophages, suggest
PACAP signaling mechanisms are involved in mediating cranial autonomic symptoms, but also in mediating dural neuro-inflammatory mecha-
nisms that contribute to dural trigeminovascular activation. CGRP, calcitonin gene-related peptide; SP, substance P; NKA, neurokinin A; VMH,
ventromedial hypothalamus; SON, supra-optic nerve, TG, trigeminal ganglion, SCG, superior cervical ganglion, PAG, periaqueductal gray; LC, locus
coeruleus; RVM, rostral ventromedial medulla
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granulocytes, natural killer (NK) cells, and NKT cells
(reviewed in Delgado [35]). All of these cell types are
present in the dura of rats, but further work needs to be
done to clarify potential actions of PACAP and VIP on
these cells.
VIP and PACAP are known to regulate T cell function
as evidenced by studies of their anti-inflammatory
actions in animal models of autoimmune/auto-inflam-
matory disease, including those modeling multiple
sclerosis, rheumatoid arthritis, and inflammatory bowel
disease. Adaptive immunity is not widely thought to
have a role in migraine, although a few studies support
this possibility (for example, [13]). In general, PACAP
and VIP promote Th2 and regulatory T cell production,
stability and function at the expense of Th1 and Th17
phenotypes. Readers are referred to ref. [35] for more
detailed information on the important actions of these
peptides in adaptive immunity.
Access of blood-born PACAP to the brain parenchyma
With a few exceptions, peptides present in the blood can-
not penetrate well into the parenchyma of most regions of
the brain due to specialized tight-junction molecules that
line endothelial cells in blood vessels within the CNS (the
endothelial component of the blood brain barrier (BBB)).
Certain structures within the brain, referred to as the
circumventricular organs lack this BBB. In particular, it is
thought that the area postrema, the subfornical organ, and
the vascular organ of lamina terminalis can receive
peptide and other blood-born signals, and transmit infor-
mation to other parts of the brain. In particular, the area
postrema is of interest because in situ hybridization shows
that PAC1 receptor gene transcripts are high in this struc-
ture. Neurons in the area postrema send major efferents
to the nucleus of the solitary tract (NTS) and the lateral
parabrachial nucleus and the hypothalamus. Minor
efferents are reported to project to several other regions
Fig. 2 Descending brainstem and cortical modulation of dural-trigeminovascular mechanisms in primary headache. Descending projections from brain-
stem nuclei including the ventrolateral periaqueductal grey (vlPAG), locus coeruleus (LC) and raphe/rostral ventromedial medullary (RVM) nuclei provide
modulation of noxious somatosensory dural-trigeminovascular inputs. Noxious peripheral inputs and central descending modulation are integrated
within trigeminocervical (TCC) neurons, the net result of which is head pain, processed within the thalamocortical neurons. Either direct activation of pre-
ganglionic pontine superior salivatory nucleus neurons from descending hypothalamic projections, or via reflex activation of trigeminal-autonomic relay,
leads to activation of the cranial parasympathetic projection, which can trigger or exacerbate the dural neuro-inflammatory cascade. Activation of cortical
neurons within the somatosensory (S1) and insulae cortices, via cortical spreading depression, and direct descending projections, can also facilitate or in-
hibit dural-trigeminovascular responses within the TCC. In addition, CSD is thought to directly mediate a neuro-inflammatory response within the dural
micro-environment to activate trigeminal primary afferent neurons that innervate the dural vasculature. CSD is proposed to activate headache by initiat-
ing a complex cascade where neurons open pannexin1 channels that activate caspase-1 and the release of pro-inflammatories such as HMGB1 and IL-
1B. Following pro-IM release, NF-KB translates to the nucleus to induce COX2 and iNOS expression in astrocytes. The activated astrocytes release cyto-
kines, prosanoids, and NO to the subarachnoid space and produce sustained activation of trigeminal nerve fibers. Trigeminal fiber collaterals produce a
sterile dural inflammation that lead to mast cell degranulation and the trigeminoparasympathetic reflex causes a late and sustained medial meningeal ar-
tery dilation (see Fig. S6 in Katata et al. [79] for more details.). In the CSD rodent model, facial grimace assessments suggest the final step in the parenchy-
mal signaling cascade outlined above produces headache
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such as the nucleus ambiguus, dorsal motor nucleus of
the vagus, dorsal regions of the tegmental nucleus, cere-
bellar vermis and ventrolateral catecholaminergic column
in the medulla [87, 127].
Glial cells in the brain parenchyma: Potential roles in
synaptic transmission and modulation by PACAP
Microglia are often viewed as the resident macrophages
of the brain. When activated, they produce and release
inflammatory molecules, including pro-inflammatory
cytokines, matrix metalloproteinases, and free radicals.
They also function in repair by secreting neuroprotective
and regenerative factors. Several in vitro studies have
demonstrated the capacity of PACAP and VIP to potently
inhibit the release of inflammatory factors from microglia
via action on VPAC and PAC1 receptors. This argues
against a role for a PACAP/microglia interaction in
migraine. On the other hand, in the uninjured brain,
microglia appear to play important roles in synapse forma-
tion (in part by secreting BDNF) and in the remodeling of
synapses in the processes of learning and memory. More-
over, glia-derived TNF-α was reported to be necessary and
sufficient for synaptic upscaling after chronic activity
blockade. Imaging studies aided with fluorescent genetic
probes have shown that microglia continually extend and
retract their processes [107]. Microglia actions such as
these are conceivably involved in the delayed migraine-
like headaches. The potential for PACAP to regulate
synaptic functions via microglia has yet to be examined.
Like microglia, astrocytes are known to secrete inflamma-
tory molecules in the settings of brain injury, neurodegen-
eration, and repair, and have important synaptic functions
in the uninjured brain. Astrocyte processes are well known
to surround synapses and express proteins that regulate
synapse function, including enzymes that control glutamate
metabolism, shuttle lactate and other energy substrates,
regulate water movement between cells, buffer potassium
ions and mediate membrane adhesion. The fact that PAC1
receptor expression is upregulated in astrocytes in several
CNS injury models such as global ischemia [103], contusion
spinal cord injury [141], and cortical stab injury [135],
suggest that PAC1 receptors in these cells might have a role
in protection and repair. PACAP was also shown to very
potently increase IL-6 production in primary cultures of rat
astrocytes [62]. Others have shown that PACAP induces
the expression of several chemokines in cultured astrocytes
including RANTES and MIP1α [22], highlighting potential
pro-inflammatory actions of PACAP on astrocytes. Perhaps
more relevant to astrocyte-mediated effects of PACAP on
synaptic activity, in vitro studies indicate that PACAP/
PAC1 signaling increases glutamate uptake via induced
expression of GLT-1/EAAT2, GLAST/EAAT1 and in-
creases glutamine synthase (GS) [121].
Specific sites within the CNS where PACAP might trigger
migraine pathophysiology
As discussed, neurogenic inflammation in relation to
primary headaches is most commonly associated with
dural mechanisms. However, several studies suggest
neuro-inflammation may also occur in other regions
of the brain. Application of the migraine trigger,
NTG, not only promotes dural changes, but also
induces neuronal activation in brainstem and higher
pain processing nuclei, such as the periaqueductal
grey and hypothalamic nuclei [140]. Cortical spread-
ing depression (CSD), believed to be the neurophysio-
logical correlate of aura in migraine [86], may induce
a cortical neuro-inflammatory cascade that leads to
activation and sensitization of the trigeminovascular
pain pathway. The remainder of this review will focus
on the role of PACAP in neurogenic inflammation,
and how this might relate to mediating primary head-
ache mechanisms.
PACAP and spinal nociception
Spinal nociception is likely to have some similar
mechanistic underpinnings as trigeminal nociception,
and is in some respects more amenable to study.
Considerable work has examined the roles of PACAP
and VIP in spinal nociception (reviewed in [38, 136]).
Like in the trigeminal ganglia, PACAP is expressed in
a subpopulation of neurons in dorsal root ganglia.
PACAP immunoreactive fibers are highly abundant in
the superficial laminae of the dorsal horn, where all
three receptors appear to be expressed. Iontophoretic
application of PACAP-38 was shown to exert excita-
tory actions on dorsal horn neurons [39]. Pharmaco-
logical studies in various acute and chronic pain
models generally support a pro-nociceptive action of
PACAP-38, and mice deficient in PACAP and PAC1
receptors fail to develop hypersensitivity to nocicep-
tive stimuli in neuropathic and inflammatory pain
paradigms. The involvement of PACAP receptors on glial
cells on sensitizing pain pathways in the spinal cord is
currently unknown, although one study showed that intra-
thecal PACAP administration resulted in long-lasting hind
paw allodynia and sustained activation of astrocytes [153].
In the target tissues, intradermal injection of PACAP was
found to induce localized pain and edema in humans and
pain-like behavior in rodents reminiscent of neurogenic
inflammation. The number of CD31+ vessel cross sections
in organotypic human skin cultures was found to be
increased in response to PACAP-38 application without
evidence of mast cell degranulation [126], whereas PACAP-
38-induced dermal edema was abolished in c-kit mutant
mice that are deficient in mast cells [122] . Thus, the role of
mast cells in the neurovascular response is unclear.
Waschek et al. The Journal of Headache and Pain  (2018) 19:23 Page 6 of 13
PACAP and the parasympathetic pathway
Cranial autonomic symptoms, such as conjunctival injec-
tion, lacrimation, nasal congestion, rhinorrhea, eyelid
edema and forehead/facial sweating, can be hugely debili-
tating, and they are a prominent and defining feature of
TACs, such as cluster headache [29, 71, 96]. They are also
prevalent in up to 50% of migraine patients [16, 17, 83].
Their presence is thought to exacerbate the general
migrainous phenotype [16, 17]. These data suggest, first, a
likely overlap of pathophysiology between migraine and
TACs as they relate to cranial autonomic symptoms; and,
second, that the presence of these symptoms may be
relevant to the pathophysiology in these primary headache
disorders, and may contribute, or even trigger trigemino-
vascular activation and sensitization.
Cranial autonomic symptoms are thought to be medi-
ated, in part, by activation of the trigeminal autonomic
reflex, and the parasympathetic autonomic projection to
the cranial vasculature [50, 63]. A reflex connection from
the TNC to the preganglionic parasympathetic neurons in
the pontine superior salivatory nucleus (SuS), is thought to
connect these two important somatosensory and auto-
nomic pathways (see Fig. 1). The SuS is the origin of cells
of the parasympathetic vasodilator pathway, and it projects
to the cranial vasculature, including the dura mater and the
lacrimal gland, predominantly via the greater petrosal nerve
(green nerve), and its synapse with the sphenopalatine
ganglion (SPG), and the VIIth (facial) nerve (light blue
nerve) [130]. Both the TNC and SuS receive descending
projections from hypothalamic and brainstem nuclei
including, the lateral and paraventricular hypothalamic
nuclei [59, 73, 74, 117, 130]. This might illustrate a mech-
anism in triggering both headache and cranial autonomic
symptoms in these primary headaches.
Activation of the cranial parasympathetic vasodilator
pathway might also influence both central trigeminovascular
neurons, and the dural microenvironment, potentially by
evoking neuro-inflammatory mechanisms. Activation of this
neurovascular pathway with its cranial autonomic symptoms
may also affect the neurophysiology related to head pain in
migraine and cluster headache. The dural blood vessels are
richly innervated by parasympathetic nerve fibers [134] and
activation of this pathway causes the release of acetylcholine
[128], VIP and NO, from dural vascular terminals of post-
ganglionic sphenopalatine neurons, also containing PACAP.
Activation can lead to dilation of intracranial vessels,
plasma protein extravasation and local dural release of
inflammatory mediators [23, 24], which may lead to a
cascade of events that ultimately produces activation of
dural-trigeminovascular neurons (see Figs. 1 and 2).
Experimentally, electrical stimulation of preganglionic SuS
neurons produces neuronal action potentials in the TCC
via two separate neural pathways. First, via retrograde acti-
vation of the trigeminal autonomic reflex, within the
brainstem. Second, however, by activation of the parasym-
pathetic outflow to the cranial vasculature, which indir-
ectly activates trigeminal afferents from the dura mater to
the TCC, as well as producing cranial autonomic symp-
toms [7, 8]. These latter responses are attenuated by the
specific SPG blocker, as well as by oxygen treatment.
Interestingly, this is not accompanied by dilation of
meningeal blood vessels [7]. These data are somewhat
paralleled by clinical studies demonstrating that SPG
blockade provides partial or complete relief of migraine
pain [152]. Finally, activation of primary afferent dural
trigeminal neurons appear to depend to some extent on
SPG activity [20]. Together, these more likely maintaining,
a state of trigeminovascular activation and sensitization.
This may be mediated via activation of the trigeminal-
autonomic reflex (most likely in maintaining the active
trigeminovascular state), descending control of trigeminal
somatosensory and SuS-autonomic via hypothalamic and
brainstem nuclei, or a combination of both, which exacer-
bate the responses of either, via the release of vasoactive
sensory neuropeptides, such as PACAP and VIP.
Despite the overwhelming data suggesting that cranial
parasympathetic activation may be important in the
modulation of trigeminovascular mechanisms related to
headache, one study suggests the contrary. In prelimin-
ary studies it was observed that low frequency stimula-
tion (LFS) of SPG seemed to trigger cluster headache in
patients. These patients had surgically implanted SPG
stimulator devices that used high frequency stimulation
for relief of cluster headache. In a double-blind randomized
sham-controlled trial, LFS was no different from ‘sham’ in
inducing cluster headache, but was significantly more likely
to produce cranial autonomic symptoms compared to
‘sham’ [63]. In the immediate phase LFS caused cluster
headache in 35% (7/20) patients, whereas ‘sham’ caused
cluster in 25% (5/20) patients. Cranial autonomic symp-
toms were present in 80% of LFS and 45% of sham patients.
The data suggest that in a rarer headache disorder, com-
pared to migraine, cranial parasympathetic activation can-
not trigger a cluster headache attack. There is an important
caveat to interpreting this data. ‘Sham’ stimulation triggered
a delayed cluster headache attack (> 1–24 h) in 75% (15/20
patients) compared to 70% (14/20 patients) in the LFS
group. The same numbers were found for the development
of cranial autonomic symptoms. With such a high rate of
response to ‘sham’ it is impossible to dissect an effect of
LFS in this delayed phase. In addition, from these data, it is
not possible to determine whether cranial parasympathetic
activation influences the maintenance of head pain, or has
a role in more common primary headache disorders, such
as migraine.
PACAP-38 and VIP are both described as parasympa-
thetic vasodilator peptides, and they are linked to cranial
autonomic symptoms in migraine and TACs. There are
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increased levels of PACAP and VIP in the extracranial vas-
culature during both spontaneous migraine [56, 142, 154]
and cluster headache [53, 143], although VIP levels during
severe migraine are only increased when accompanied by
cranial autonomic symptoms. Furthermore, both cause
cranial autonomic symptoms [11, 114, 124] when given
exogenously in patients, which is suggestive of activation of
the parasympathetic autonomic fibers that project to the
cranial vasculature. In support of the important role of
PACAP and VIP in the cranial parasympathetic pathway
there is evidence of both peptides in human SPG localized
in neurons, and often co-localised with nitric oxide
synthase [31]. There is also evidence of VPAC1, VPAC2
and PAC1 receptor expression in both human and rat SPG,
but not co-localised with the PACAP and VIP [31]. There
is also preliminary data suggesting that VPAC1 and PAC1
receptor antagonists are able to inhibit both cranial
autonomic and trigeminocervical neuronal responses after
stimulation of the SuS [4]. Together these data suggest that
the cranial parasympathetic projection is ideally placed to
mediate dural neuro-inflammatory mechanisms that con-
tribute to trigeminovascular activation in primary head-
aches. Further, that PACAP-mediated signaling is the most
likely pharmacological class involved in this pathway, and a
potential target loci and pharmacology for therapeutic
intervention.
PACAP, stress, and the sympathetic nervous system.
Stress is a major trigger of migraine, suggesting that stress
centers in the brain and the sympathetic nervous system
play a role in migraine. PACAP is well known as a master
regulator of the stress response, acting with the CNS and
peripheral nervous system to increase sympathetic activity
(reviewed in [46, 68, 119, 149]). In this regard, PACAP/
PAC1 signaling is critically required in the hypothalamus
to mediate the induction of the hypothalamic-pituitary
adrenal axis and likely plays a role in other areas of the
CNS that mediate responses to emotional and other types
of stress, such as the amygdala, bed nucleus of the stria
terminalis, and locus coeruleus (reviewed in [64]). PACAP
could potentially trigger migraine by modulating neuro-
transmission in the brain areas involved in stress by direct
action on neurons, or by triggering astroglial and
microglial neuro-inflammatory responses. PACAP is also
expressed in the acetylcholine-expressing preganglionic
neurons in the spinal cord that innervate the sympathetic
ganglia [19, 111], whereas PAC1 receptors are expressed
in the postganglionic sympathetic neurons [21, 48].
PACAP-induced sympathetic activity in dural blood ves-
sels could thus trigger migraine in susceptible individuals.
PACAP and the brainstem
The role of brainstem nuclei in the pathophysiology of
primary headaches, particularly migraine, has been
extensively reviewed [6, 24, 57]. There is activation within
brainstem nuclei, likely periaqueductal grey (PAG), locus
coeruleus (LC) and raphe nuclei [1–3, 15, 92, 151], in
addition to hypothalamic activation [36, 92], during the
premonitory and headache phases that appear specific to
a migraine attack. Central trigeminovascular neurons are
under the control of pain modulatory circuits in the brain-
stem. This is clearly demonstrated in preclinical studies in
rodents that show that descending projections from PAG,
LC, raphe and rostral ventromedial medullary (RVM)
neurons [43, 80–82, 84, 90, 91] are able to modulate
noxious and non-noxious intracranial-dural somatosen-
sory inputs within central trigeminovascular neurons
(Fig. 2). Whether these brainstem nuclei are involved in
triggering a migraine attack, or mediating changes within
central trigeminovascular neurons that results in hyper-
sensitive responses to normal and/or noxious stimuli
coming from intracranial structures, such as the dura
mater, within an attack is still debated. However, central
trigeminovascular neurons are known as integrative relay
neurons between peripheral and central pain mechanisms.
Thus, the net result of activation, of nociceptive intracra-
nial dural structures, and altered (dysfunctional) descend-
ing modulation of central trigeminovascular neurons, in
headache, is due to an altered perception of craniovascular
inputs, and also a generalized increase in sensitivity of
other sensory inputs, via the modulation by these same
brainstem nuclei.
PACAP and its receptors are ideally positioned to play
an important role in these processes. Aside from
exogenous PACAP triggering migraine attacks in migrai-
neurs, PACAP is released endogenously during a migraine
attack [142, 154]. Indeed, even during exogenously-
triggered migraine with PACAP-38, levels within the
cranial vasculature are higher than would be anticipated
at time of sampling, suggesting that these headaches are
also mediated by endogenous release of PACAP [11].
Overall this suggests PACAP-38 within the brainstem
may have a physiological role to play in the pathophysi-
ology of migraine. In support of this, immunoreactivity
to PACAP-38 is present in approximately 40% of LC
neuronal cells, and a smaller population within the
PAG [137]. There is also evidence of receptor binding
specific to PACAP in the LC, PAG and also dorsal
raphe nuclei, which is indicative of PAC1 binding [95].
Studies into the role of PACAP-mediated mechanisms
within the brainstem in primary headache pathophysi-
ology are in their infancy compared to other neuropep-
tides, such as CGRP. However, it is possible that
manipulation of PACAP containing pathways differen-
tially modulates noxious and innocuous intra and
extra-cranial somatosensory processing, similar to
mechanisms described within the paraventricular hypo-
thalamic nucleus [117].
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Evidence of PACAP-mediated neuro-inflammatory mech-
anisms within the brainstem in migraine is limited.
However, previous studies demonstrate that application of
nitroglycerin, another exogenous trigger of migraine, causes
increased expression of COX-2, which promotes the pro-
duction of prostaglandins, including prostaglandin E2 [139].
Also, activation of microglia and astrocytes within the PAG
[41, 99, 105], LC [104, 155] and raphe/RVM nuclei [37,
150] is evident during various forms of neuropathic pain,
resulting in the release of inflammatory mediators. There is
evidence of activation of glial cells proximate to trigeminal
neurons in various animal models of migraine and craniofa-
cial pain [30, 45, 66, 144], which might suggest there is
similar activation in brainstem nuclei. At the moment, there
is still much to be learned about neuroimmune responses
during primary headaches, particularly in the brainstem.
The established importance of PACAP and the PAC1
receptors in other immune responses suggest they are also
likely to play an important role in primary headache.
PACAP and cortical mechanisms
First identified in the 1940s, cortical spreading depression
(CSD) is a profoundly disruptive neurovascular event that
results in a large DC potential shift, the reversible loss of
ionic homeostasis, and multi-phasic changes in blood
oxygenation and blood vessel constriction-dilatation
dynamics. These electrochemical and vascular events are
iterated slowly across the cortex as a propagating wave
that travels both across and within the cortex. CSD is
present in some of the brain injury models remarked upon
earlier (e.g., global ischemia, cortical stab) and is believed
to be the operant mechanism that produces visual aura in
migraine. CSD tends to correlate with more dire outcomes
in cases of hemorrhagic stroke. The parenchymal and
vascular changes observed in animal models tend to
return to normalcy after about an hour. Such sustained
changes in neurovascular dynamics observed in spontan-
eous CSD as may occur in migraine likely includes many
of the same PACAP mediated changes (e.g., astrocyte acti-
vation, changes in glutamate regulation, PACAP mediated
changes in neuro-inflammation) observed in brain injury
models. Interestingly, astrocytes can be selectively acti-
vated optogenetically to elicit CSD and preliminary studies
suggest that astrocytes may be in fact activated many
seconds before the typical markers of CSD are observed.
Thus, astrocyte involvement in neuro-inflammatory events
related to CSD warrants further investigation.
As detailed in Fig. 2, CSD may also produce not only a
perceptual hallucination like visual aura in migraine, but
may also be involved in the activation of a parenchymal
cascade that leads to headache. In brief, CSD is proposed
to activate headache by initiating a complex cascade
where neurons open pannexin1 channels that activate
caspase-1 and the release of pro-inflammatory molecules
such as HMGB1 and IL-1B. Following pro-inflammatory
mediator release, NF-KB translates to the nucleus to
induce COX2 and iNOS expression in astrocytes. The
activated astrocytes release cytokines, prosanoids, and
NO to the subarachnoid space to produce sustained
activation of trigeminal nerve fibers. Trigeminal fiber
collaterals produce a sterile dural inflammation that lead
to mast cell degranulation and the trigeminoparasympa-
thetic reflex causes a late and sustained medial menin-
geal artery dilation (see Fig. S6 in Katata et al. [79]. for
more details on their proposed model). In the CSD
rodent model, facial grimace assessments suggest the
final step in the parenchymal signaling cascade outlined
above produces headache. Some notes of caution are
warranted in interpreting the cascade as 1 M KCl was
topically applied to the dura and may produce some of
the changes observed independently of CSD. The
changes observed were also following multiple CSDs
elicited in a small window of time, which is not charac-
teristic of clinical migraine. Using optogenetic and
chemogenetic methods to directly target specific cellular
targets in chronic models of CSD may overcome some
of the difficulties in interpreting and validating the
prevailing model.
Very preliminary studies using PACAP KO mice show
changes in CSD (SMB, JW, unpublished observations).
This is not terribly surprising given the strong vasodila-
tory effects of PACAP, but changes in the parenchymal
intrinsic optical signal—which is a mixed signal of neural
and glial activity, as well as blood volume and oxygen-
ation, was also noted (IL, SMB, AC, JW, unpublished
observations). Further work is needed to verify these re-
sults and to examine post-CSD cascades in animals with
modified PACAP signaling. For example, targeting
PACAP receptor sub-types and using inducible animal
models to rule out compensatory mechanisms will help
to delineate the role PACAP plays in CSD.
Despite the multifactorial effects of CSD on brain
pathophysiology, it is important to remember that many
people with migraine do not experience visual aura and
some with visual aura do not report headache. This may
in part be explained by where CSD is initiated, how CSD
is triggered, and the extent and size of CSD changes in
terms of cortical boundaries and layers. There may also
be important gating mechanisms that determine whether
neuro-inflammatory responses are triggered.
Conclusion
PACAP, and activation of its receptor subtypes, clearly
have a very important role in the pathophysiology of
primary headache disorders. Undoubtedly this includes
actions within the trigeminovascular system to activate
this nociceptive pathway. However, there are also likely
actions away from this medullary region, in other brain
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parenchyma that have direct actions related to headache
pathophysiology and symptoms, as well as indirect actions
involved in the modulation of dural-trigeminovascular
neurotransmission. Further, the role of inflammatory
mediators is likely to be intrinsic to PACAP’s mechanism
of action in headache pathophysiology. In this review, we
have outlined the potential role of PACAP and its recep-
tors in neuro-inflammatory mechanisms, and how they
might be related to primary headache pathophysiology. In
addition, we have discussed how neuromodulatory and
neuro-inflammatory mechanisms of PACAP within the
brain parenchyma might also be involved in modulating
dural-inflammatory mechanisms related to trigeminovas-
cular activation and headache pathophysiology.
Our understanding of the exact role(s) of PACAP in
primary headache pathophysiology is in its infancy, with
much of the current research focused on its role within
the trigeminovascular system, its dural innervation, and
related dural inflammatory processes. There has been
seminal work in dissecting some of these mechanisms,
and identifying the likely PACAP receptor subtypes
responsible for these actions. However, it seems that the
future of this research may move away from this region
and concentrate within other structures, such as the
brainstem and higher nuclei, the cortex and autonomic
pathways. This research is likely to concentrate on the
role of PACAP in mediating associated symptoms
related to primary headaches, such as migraine aura,
autonomic phenomena, generalized sensory hypersensi-
tivity and symptoms of homeostatic disturbance, as well
as headache itself. With the emerging importance of
PACAP in the pathophysiology of primary headache
disorders, there is also ongoing development of thera-
peutics to target PACAP and its receptors in the context
of primary headaches. This has largely followed the
successful roadmap of development of CGRP-related
therapeutics, with a current focus on the development of
PACAP-related antibodies, targeting both PACAP and
the PAC1 receptor. While preliminary data suggest that
targeting PAC1 receptors might be most efficacious, we
also outline arguments that targeting VPAC1 and
VPAC2 receptors may still hold clinical relevance.
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